MedPath

First-in-human testing of the Flume urinary catheter (a tube inserted to remove urine)

Not Applicable
Terminated
Conditions
A new urinary catheter designed to improve bladder drainage
Urological and Genital Diseases
Registration Number
ISRCTN11705129
Lead Sponsor
orth Bristol NHS Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Stopped
Sex
All
Target Recruitment
15
Inclusion Criteria

Stage 1
1. Adults (>=18 years) of either gender, who are willing to participate in the study and give their written informed consent.
2. Subjects who are due to undergo planned general anaesthetic cystoscopy (routine endoscopic bladder inspection) – stage 1a only.
3. Subjects who are due to undergo a urological operation for which an indwelling catheter is routinely used – stage 1b only.

Stage 2
1. Adults (>= 8 years) of either gender.
2. Patients who need an indwelling urinary catheter as a method of bladder drainage for at least one month.
3. Patients who are willing and able to participate in the study and give their written informed consent.
4. Established catheter users. (Defined as had a Foley catheter for at least the last 6 months and anticipate continuing to use one for at least the next 3 months”).

Exclusion Criteria

Stage 1
1. Catheter-associated UTI at time of assessment, according to National Healthcare Safety Network (NHSN) surveillance and clinical criteria. One re-screen per subject is allowed, once the infection has been treated, the patient is eligible for the study. (https://www.cdc.gov/nhsn/index.html)
2. Participants who are on systemic antibiotics within 48 hours prior to enrolment.
3. Patient with a known allergy to any of the materials used in the FLUME catheter.
4. Patient has urinary tract anatomic abnormality that would prevent placement of a standard Foley catheter.
5. Informed consent cannot be obtained (See Section 12 for assessment of capacity).
6. Patient is breast feeding or pregnant, confirmation that the women is not pregnant will be determined by [1] clear indication of menopause, [2] time since last menstruation or [3] confirmation of abstinence. Women of child-bearing age will be asked to perform a pregnancy test if applicable after obtaining their consent.
7. Patients who have undergone a TURP (Transurethral resection of the prostate) within the last 3 months.
8. Patients for whom a Fr14 sized dual lumen catheter would be inappropriate.

Stage 2
1. Catheter-associated UTI at time of assessment, according to National Healthcare Safety Network (NHSN) surveillance and clinical criteria. One re-screen per subject is allowed, once the infection has been treated, the patient is eligible for study. This will be recorded through self reporting of symptoms and/or prescribed antibiotics.
2. Participants who are on systemic antibiotics within 48 hours prior to enrolment.
3. Patient currently taking (or expected to take) more than a single dose of antibiotics for prevention of other infections during the catheter indwell period.
4. Suprapubic catheter user.
5. Patient with a known allergy to polyurethane or silicone used in the FLUME or comparator catheter.
6. Patient has urinary tract anatomical abnormality that would prevent placement of a standard Foley catheter.
7. Informed consent cannot be obtained.
8. Patient is unable or unwilling to comply with the study follow-up schedule.
9. Patient is breastfeeding woman or pregnant (confirmation that the woman is not pregnant will be determined by [1] clear indication of menopause, [2] time since last menstruation or [3] confirmation of abstinence. Women of child-bearing age will be asked to perform a pregnancy test if applicable (after obtaining their consent).
10. New catheter users.
11. Patients for whom scheduled catheter changes are more frequent than monthly.
12. Cognitive impairment affecting ability to complete outcome assessments (in the opinion of the investigator).
13. Patients who have undergone a TURP (Transurethral resection of the prostate) within the last 3 months.
14. Patients for whom a Fr14 sized dual lumen catheter would not be appropriate.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.